Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India
- Glenmark has received the DCGI’s approval to initiate P-III FAITH study assessing Favipiravir + Umifenovir + SOC and Favipiravir + SOC in 158 hospitalized patients with moderate COVID-19. On day 1- patients will receive Faviprivir (1800mg- bid) and Umifenovir (800mg- bid)- followed by 800mg of each for the remaining course of the treatment
- Treatment duration of the study is 14days and patients will be discharged after clinical cure & two consecutive negative tests for COVID-19 based on RT-PCR. The two antivirals with different MOA complement and enhance efficacy against COVID-19
- Additionally- Glenmark is evaluating Favipiravir in P-III clinical study as monothx. with 150 patients with COVID-19 with its anticipated results in Jul/ Aug’2020. Glenmark is the first company to receive DCGI’s approval to conduct clinical trials of Favipiravir against COVID-19 in India
Click here to read full press release/ article | Ref: Glenmark | Image: Glenmark
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].